Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06096-x ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of Hematology, 2024. Verfasst von S Mathur und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Manitoba, Winnipeg, Canada. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Registries, Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: University of Manitoba.
Abstract (Originalsprache)
Infections are a significant cause of morbidity and mortality in myelodysplastic syndrome (MDS). Precise estimates of infection frequency and severity with modern therapies are uncertain. We conducted a retrospective analysis of a prospective cohort enrolled in a Canadian MDS registry and characterized the frequency and severity of infectious complications. Among 1,115 patients enrolled in the registry from 2006 to 2022, 349 (31%) experienced fever/infection, 207 (19%) were hospitalized due to fever/infection, and 95 (9%) died from fever/infection. Patients with severe neutropenia (absolute neutrophil count 3.5) had more fever/infection (36% vs. 29%; p = 0.05), infection-related hospitalizations (24% vs. 14%; p < 0.01), and a trend toward higher mortality due to fever/infection (11% vs. 7%; p = 0.06). Hypomethylating agent (HMA) treatment was associated with higher rates of fever/infection (40% vs. 26%; p < 0.01), as well as increased infection-related hospitalization (27% vs. 14%; p < 0.01) and death (14% vs. 6%; p < 0.01). Multivariate analysis showed that higher-risk disease and HMA treatment contributed to poorer infection-related outcomes including a shorter time from diagnosis to fever/infection (HR 1.9; p < 0.01 and HR 1.8; p < 0.01, respectively), hospitalization (HR 2.5; p < 0.01 and HR 1.9; p < 0.01, respectively), and death (HR 2.3; p = 0.01 and HR 3.3; p < 0.01, respectively). In a Canadian MDS population, infectious events were common with baseline neutropenia, higher-risk disease, and hypomethylating agents associated with increased infection risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.
- Division of Hematology, The Ottawa Hospital, Ottawa, Canada.
- Hematology, CHU De Québec-Université Laval, Quebec City, Canada.
- Hematology, Saskatchewan Cancer Agency, Saskatoon, Canada.
- Hematology, Dr. Georges-L-Dumont University Hospital Centre, Moncton, Canada.
- Hematology, Tom Baker Cancer Centre, Calgary, Canada.
Förderung
- University of Manitoba
Zitieren
APA
Mathur, S., Christou, G., Delage, R., Elemary, M., Finn, N., Geddes, M., Houston, D. S., Keating, M. M., Khalaf, D., Leber, B., Leitch, H., Lother, S. A., Mozessohn, L., Nevill, T., Parmentier, A., Paulson, K., Rimmer, E., Sabloff, M., Shamy, A., …, & Houston, B. L. (2024). Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry. Annals of Hematology. https://doi.org/10.1007/s00277-024-06096-x
Vancouver
Mathur S, Christou G, Delage R, Elemary M, Finn N, Geddes M, et al. Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry. Annals of Hematology. 2024. doi:10.1007/s00277-024-06096-x
BibTeX
@article{Mathur2024,
author = {Mathur, S and Christou, G and Delage, R and Elemary, M and Finn, N and Geddes, M and Houston, D S and Keating, M M and Khalaf, D and Leber, B and Leitch, H and Lother, S A and Mozessohn, L and Nevill, T and Parmentier, A and Paulson, K and Rimmer, E and Sabloff, M and Shamy, A and St-Hilaire, E and Storring, J and Yee, K and Zhang, L and Zhu, N and Hay, A E and Zarychanski, R and Buckstein, R and Houston, Brett L},
title = {Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06096-x}
}
EUVIMED